GLUCO-NAF WITH VITAMIN D

Indications

• Vitamin D deficiency
• Osteoporosis
• Rickets
• Hypoparathyroidism
• Renal osteodystrophy

Mechanism of action

For its activity, ergocalciferol must be transformed into its major active metabolite and transported to target organs to bind to the vitamin D receptor. This receptor activation, part of the vitamin D endocrine system, alters transcription rates of vitamin D receptor target genes. Ergocalciferol also has nongenomic effects such as stimulating intestinal calcium transport. The mechanism of calcitriol, the activated form of vitamin D, involves binding to cytosolic receptors, which then interact with DNA to modulate gene transcription, similar to steroid and thyroid hormones.

Pharmacodynamics

After activation of the vitamin D receptor, ergocalciferol induces several biological changes, including the mobilization and accretion of calcium and phosphorus in bone, intestinal absorption of these minerals, and renal reabsorption. It promotes osteoblast formation, fetal development, pancreatic function, neural function, immune response, cellular growth, and differentiation. Compared to cholecalciferol, ergocalciferol is less potent due to reduced induction of calcidiol. In patients with end-stage renal disease, ergocalciferol supplementation has shown significant benefits in bone and mineral metabolism, glycemic control, serum albumin levels, and inflammatory markers.

Pharmacokinetics

The pharmacokinetics of ergocalciferol involves its absorption in the gastrointestinal tract, conversion to active metabolites in the liver and kidneys, and subsequent distribution to various tissues. The bioavailability can be influenced by dietary fat and the presence of certain medical conditions. The half-life of ergocalciferol is approximately 15 days, and it is stored in fat tissues. Its elimination primarily occurs through hepatic metabolism and biliary excretion.

Adverse effects

• Nausea
• Vomiting
• Constipation
• Weakness
• Weight loss
• Bone pain
• Kidney stones
• Hypercalcemia

Interactions

• Anticonvulsants may reduce the effectiveness of ergocalciferol
• Thiazide diuretics may enhance the risk of hypercalcemia when used with ergocalciferol
• Magnesium-containing antacids may increase the risk of hypermagnesemia

Precautions

• Monitor calcium levels periodically during therapy
• Use with caution in patients with a history of kidney stones
• Caution in patients with hyperparathyroidism

Pregnancy

Ergocalciferol is generally considered safe during pregnancy when used as directed, but it should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Ergocalciferol is excreted in breast milk; however, the amounts are typically not expected to be harmful to the nursing infant.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Formulations

• Capsules
• Oral solution
• Tablets

Dosage

Children: Refer to specific drug information for detailed dosage recommendations.

Adults: Refer to specific drug information for detailed dosage recommendations.

Mechanism of action

The mechanism of action varies depending on the specific drug that 'contains' certain active ingredients. Each compound will have its own unique pharmacological pathway and target within the body, which can include receptor modulation, enzyme inhibition, or other biochemical interactions.

Pharmacodynamics

Pharmacodynamics will depend on the active ingredients in the formulation. It generally encompasses the biochemical and physiological effects of the drug and its mechanisms of action, including the relationship between drug concentration and effect.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion of the specific active ingredients within the formulation. This can vary significantly based on the drug's chemical properties, route of administration, and individual patient factors.

Pregnancy

Consult with a healthcare provider before use, as safety during pregnancy has not been established.

Breast-feeding

Consult with a healthcare provider before use, as it is not known if this drug is excreted in human milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Hypoglycemia
• Caloric supplementation in patients unable to eat
• Fluid replacement therapy
• Parenteral nutrition

Dosage

Children: Paediatric doses must be determined based on clinical condition and specific needs. Refer to the BNF for Children for appropriate dosing information.

Adults: The dosage of dextrose in adults varies based on clinical condition and route of administration. For hypoglycemia, intravenous dextrose 50% (D50W) is commonly administered. Refer to the BNF for specific dosing guidelines.

Mechanism of action

Dextrose supplies energy to tissues by generating ATP and NADH through glycolysis, where glucose is phosphorylated by hexokinase to form glucose 6-phosphate. This activates glucose for breakdown, ultimately converting glucose into energy molecules. Dextrose also plays a role in gene transcription, enzyme activity, and hormone secretion, regulating glucose homeostasis and cellular metabolic integrity.

Pharmacodynamics

Blood glucose acts as a crucial energy source for cellular activities and functions as a signaling molecule. It is oxidized into carbon dioxide and water, producing energy through glycolysis, the citric cycle, and oxidative phosphorylation. Dextrose can be converted into fat for energy storage and is stored as glycogen in the liver and muscles. Its administration, particularly orally, enhances insulin secretion due to stimulation of incretin hormones.

Pharmacokinetics

Dextrose is rapidly absorbed in the gastrointestinal tract, leading to a quick elevation of blood glucose levels. It is distributed throughout the body and can be utilized by various tissues for energy. The metabolism of dextrose primarily occurs in the liver, where it can be stored as glycogen or converted into fat. Renal excretion may occur when blood glucose levels are excessively high.

Adverse effects

• Hyperglycemia
• Fluid overload
• Hypokalemia
• Thrombophlebitis at injection site

Interactions

• Corticosteroids may increase blood glucose levels
• Beta-blockers may mask symptoms of hypoglycemia
• Diuretics may cause electrolyte imbalances

Precautions

• Use with caution in patients with diabetes mellitus
• Monitor blood glucose levels regularly
• Use cautiously in patients with renal impairment or heart failure

Pregnancy

Dextrose is generally considered safe for use during pregnancy when clinically indicated, but should be used with caution.

Breast-feeding

Dextrose can be used during breastfeeding as it is a natural sugar found in breast milk.

Storage

Store at room temperature, away from direct sunlight, and protect from freezing.

Formulations

• Dextrose 5% solution for infusion
• Dextrose 10% solution for infusion
• Dextrose 50% solution for injection
• Oral dextrose tablets

Indications

• Constipation
• Topical moisturizer for dry skin
• Ocular lubricant in eye drops

Dosage

Children: Refer to BNF for Children for specific dosing based on age and weight.

Adults: Refer to clinical guidelines for specific dosing based on the formulation and indication.

Mechanism of action

Glycerol acts as an osmotic agent, drawing water into the intestines, which helps to soften stools and promote bowel movements. It increases the osmotic pressure in the intestinal lumen, aiding in the treatment of constipation. Additionally, glycerol may provide hydration to the skin and mucous membranes due to its hygroscopic properties.

Pharmacodynamics

Glycerol has a low molecular weight and is easily absorbed by the body. Its osmotic effects help to increase the water content in the intestines, facilitating stool passage. In topical applications, glycerol enhances skin hydration, improving skin barrier function and reducing transepidermal water loss.

Pharmacokinetics

Glycerol is absorbed from the gastrointestinal tract and distributed throughout the body. It is metabolized primarily in the liver, where it can be converted into glucose or fatty acids. The elimination of glycerol occurs mainly through renal excretion, with a half-life of approximately 1.5 to 3 hours. It has a volume of distribution of about 0.4 to 0.6 L/kg.

Pregnancy

Glycerol is generally considered safe for use during pregnancy, but it is advisable to consult a healthcare provider before use.

Breast-feeding

Glycerol is excreted in breast milk in small amounts, and caution should be exercised when administering it to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Glycerol oral solution
• Glycerol suppositories
• Glycerol topical preparations

Indications

• Nutritional supplementation
• Support in metabolic disorders
• Potential use in sports nutrition

Dosage

Children: Refer to the BNF for Children for appropriate dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Glycerophosphate serves as a substrate for the synthesis of phospholipids and triglycerides. It is metabolized to dihydroxyacetone phosphate, which is involved in glycolysis and gluconeogenesis, thereby participating in energy production. It may also promote the formation of ATP, enhancing cellular energy availability.

Pharmacodynamics

Glycerophosphate functions in cellular metabolism as a key intermediate in the synthesis of nucleotides and phospholipids. It aids in the regulation of osmotic balance and may influence cell signaling pathways, including those associated with growth and differentiation.

Pharmacokinetics

Glycerophosphate is absorbed in the gastrointestinal tract and is distributed throughout body tissues. It is metabolized primarily in the liver and muscle tissues, with its metabolites being excreted through urine. The half-life of glycerophosphate is variable based on tissue distribution and metabolic demand.

Pregnancy

There is no established safety profile for glycerophosphate use in pregnancy. Consult relevant guidelines and literature before prescribing.

Breast-feeding

Safety during breastfeeding has not been established. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• {'formulation': 'Glycerophosphate oral solution', 'strength': None}
• {'formulation': 'Glycerophosphate injection', 'strength': None}

Mechanism of action

For its activity, ergocalciferol is required to be transformed to its major active circulating hydroxylated metabolite and transported to the target organs in order to bind to its target, the vitamin D receptor. The activation of the vitamin D receptor is part of the vitamin D endocrine system and it is described by the production of a change in the transcription rates of the vitamin D receptor target genes. The target genes in the DNA affected by the presence of ergocalciferol are called vitamin D response elements which are dependent on co-modulators. The vitamin D receptor is a transcription factor and member of the steroid hormone nuclear receptor family. It presents a DNA binding domain (VDRE) that, when activated, recruits coregulatory complexes to regulate the genomic activity. Additionally, ergocalciferol presents nongenomic effects such as the stimulation of intestinal calcium transport via transcaltachia. The mechanism of action of calcitriol, the activated form of vitamin D, resembles that of the steroid and thyroid hormones. Thus, calcitriol binds to cytosolic receptors within target cells, and the receptor-hormone complex interacts with the DNA of certain genes to either enhance or inhibit their transcription. Structural analysis of the calcitriol receptor indicates that it belongs to the same supergene family as the steroid receptors. Calcitriol also appears to exert a few effects that occur too rapidly to be explained by genomic actions. /Calcitriol/ The mechanisms responsible for mobilization of bone salts have been only partially defined, and the interaction of multiple factors appears to be involved. Paradoxically, the cells responsible for bone resorption (osteoclasts) are not directly acted upon by calcitriol and do not appear to contain calcitriol receptors. Instead, calcitriol causes an increase in the number of osteoclasts available to resorb bone; this may result from an action upon myeloid hematopoietic precursor cells that are induced to differentiate toward functional osteoclasts. The cells responsible for bone formation (osteoblasts) do contain receptors, and calcitriol causes them to elaborate several proteins, including osteocalcin, a vitamin K-dependent protein that contains gamma-carboxyglutamic acid residues. The exact role of this protein is not known, but other unidentified substances are also elaborated that appear to stimulate the function of osteoclasts. In addition, calcitriol acts synergistically with gamma-interferon to increase the production of interleukin-1, a lymphokine that promotes bone resorption.

Pharmacodynamics

After the activation of the vitamin D receptor, some of the biological changes produced by ergocalciferol include mobilization and accretion of calcium and phosphorus in the bone, absorption of calcium and phosphorus in the intestine, and reabsorption of calcium and phosphorus in the kidney. Some other effects known to be produced due to the presence of vitamin D are osteoblast formation, fetus development, induction of pancreatic function, induction of neural function, improvement of immune function, cellular growth and cellular differentiation. When compared to its vitamin D counterpart [cholecalciferol], ergocalciferol has been shown to present a reduced induction of calcidiol and hence, it is less potent. Ergocalciferol supplementation in patients with end-stage renal disease has been shown to generate a significant benefit in lab parameters of bone and mineral metabolism as well as improvement in glycemic control, serum albumin levels and reduced levels of inflammatory markers.

Mechanism of action

Glucose supplies most of the energy to all tissues by generating energy molecules ATP and NADH during a series of metabolism reactions called glycolysis. Glycolysis can be divided into two main phases where the preparatory phase is initiated by the phosphorylation of glucose by hexokinase to form glucose 6-phosphate. The addition of the high-energy phosphate group activates glucose for the subsequent breakdown in later steps of glycolysis and is the rate-limiting step. Products end up as substrates for following reactions, to ultimately convert C6 glucose molecule into two C3 sugar molecules. These products enter the energy-releasing phase where the total of 4ATP and 2NADH molecules are generated per one glucose molecule. The total aerobic metabolism of glucose can produce up to 36 ATP molecules. These energy-producing reactions of glucose are limited to D-glucose as L-glucose cannot be phosphorylated by hexokinase. Glucose can act as precursors to generate other biomolecules such as vitamin C. It plays a role as a signaling molecule to control glucose and energy homeostasis. Glucose can regulate gene transcription, enzyme activity, hormone secretion, and the activity of glucoregulatory neurons. The types, number, and kinetics of glucose transporters expressed depends on the tissues and fine-tunes glucose uptake, metabolism, and signal generation to preserve cellular and whole body metabolic integrity. Vascular calcification is a hallmark of type 2 diabetes. Glucose stimulates calcification in culture of vascular smooth muscle cells (VSMCs) but the underlying mechanisms remain obscure. We observed that high glucose levels stimulated mouse and human VSMC trans-differentiation into chondrocytes, with increased levels of Sox9, type II collagen, glycosaminoglycan and Runx2 expression, and increased alkaline phosphatase activity and mineralization. These effects were associated with increased expression of IL-1beta, which stimulated alkaline phosphatase and calcification, suggesting that glucose induces chondrocyte differentiation of VSMCs, possibly through IL-1beta activation.

Pharmacodynamics

Blood glucose is an obligatory energy source for humans involved in various cellular activities, and it also acts as a signaling molecule for diverse glucose-sensing molecules and proteins. Glucose undergoes oxidation into carbon dioxide, water, and yields energy molecules in the process of glycolysis and subsequent citric cycle and oxidative phosphorylation. Glucose is readily converted into fat in the body which can be used as a source of energy as required. Under a similar conversion into storage of energy, glucose is stored in the liver and muscles as glycogen. Glucose stores are mobilized in a regulated manner, depending on the tissues' metabolic demands. Oral glucose tablets or injections serve to increase the supply of glucose and oral glucose administration is more effective in stimulating insulin secretion because it stimulates the incretin hormones from the gut, which promotes insulin secretion.